271 related articles for article (PubMed ID: 34425876)
41. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
42. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
43. 2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies.
Raimondi V; Ciotti G; Gottardi M; Ciccarese F
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740380
[TBL] [Abstract][Full Text] [Related]
44. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract][Full Text] [Related]
45. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia.
Yue Z; Pan C; Wang S; N Tse A; Sheng Y
Eur J Clin Pharmacol; 2024 Jan; 80(1):105-113. PubMed ID: 37917187
[TBL] [Abstract][Full Text] [Related]
46. The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia.
Zhuang X; Pei HZ; Li T; Huang J; Guo Y; Zhao Y; Yang M; Zhang D; Chang Z; Zhang Q; Yu L; He C; Zhang L; Pan Y; Chen C; Chen Y
Front Oncol; 2022; 12():931462. PubMed ID: 35814406
[TBL] [Abstract][Full Text] [Related]
47. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
[No Abstract] [Full Text] [Related]
48. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
49. Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
Megherea O; Janes C; Kowalski A; Baron J; Ahn E; Soule A; Newman M
Leuk Lymphoma; 2021 Dec; 62(13):3219-3225. PubMed ID: 34313176
[TBL] [Abstract][Full Text] [Related]
50. Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design.
Poonan P; Peters XQ; Soliman MES; Alahmdi MI; Abo-Dya NE
Anticancer Agents Med Chem; 2023; 23(8):953-966. PubMed ID: 36453510
[TBL] [Abstract][Full Text] [Related]
51. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
52. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
53. Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents.
Khalil AF; El-Moselhy TF; El-Bastawissy EA; Abdelhady R; Younis NS; El-Hamamsy MH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2157411. PubMed ID: 36629449
[TBL] [Abstract][Full Text] [Related]
54. Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment.
Reed DR; Elsarrag RZ; Morris AL; Keng MK
Cancer Manag Res; 2019; 11():8073-8080. PubMed ID: 31564968
[TBL] [Abstract][Full Text] [Related]
55. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
56. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
57. Synthetic lethal vulnerabilities of cancer.
Fece de la Cruz F; Gapp BV; Nijman SM
Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
59. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
[TBL] [Abstract][Full Text] [Related]
60. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
